Health Care

NIH’s top doctor talks Ebola, health, and what keeps him up at night.

Transforming grief into drive to transform the medical world. MedImmune head Bahija Jallal leads the push to bring a new kind of science to biotech heavyweight AstraZeneca.

Valeant Pharmaceuticals agreed on Monday to buy Medicis Pharmaceutical for $44 per share, a 39% premium to Medicis stock's closing price of $31.56 on Friday.

Regulators extended its review of Pfizer's experimental rheumatoid arthritis treatment tofacitinib, one of the most promising new drugs in the company's pipeline.

The $8.50-a-share deal represents a 27% premium on the cancer treatment maker's Tuesday closing price.

The largest U.S. pharmacy chain's results trailed forecasts as store traffic reversed.

New documents show the Obama administration was aware the SHOP insurance exchange needed to be delayed as early as August, but waited until Nov. 27 to announce the news.

FOX Business interviewed chief executives from GlaxoSmithKline, Humana, AthenaHealth and others at the second annual Forbes Healthcare Summit in New York City.

Deadlocked: The partial government shutdown could last weeks, leaving countless impacted businesses across the U.S. preparing for the worst.

A Chinese meat company's plan to buy U.S.-based Smithfield Foods has some lawmakers worried the deal could create food safety issues.

The drug maker's bottom line exceeded forecasts, but it suffered weaker-than-expected sales due to generic competition. 

President Obama addressed glitches with the Affordable Care Act's registration process since its rollout two weeks ago. 

The buyout carries a hefty premium of 85.5% and values the smaller medical-device maker at $1.65 billion.

Rite-Aid announced plans on Friday to issue a new $500 million second-lien term loan, and narrowed the high-end of its full-year guidance by a penny.

The generic drugmaker said it was in early stage discussions to buy the specialty pharmaceutical company Warner Chilcott.  

Pfizer’s board of directors approved an 8% increase in the drug maker’s quarterly dividend.